262 related articles for article (PubMed ID: 11134513)
21. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase.
Kijima M; Yoshida M; Sugita K; Horinouchi S; Beppu T
J Biol Chem; 1993 Oct; 268(30):22429-35. PubMed ID: 8226751
[TBL] [Abstract][Full Text] [Related]
22. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.
Bantscheff M; Hopf C; Savitski MM; Dittmann A; Grandi P; Michon AM; Schlegl J; Abraham Y; Becher I; Bergamini G; Boesche M; Delling M; Dümpelfeld B; Eberhard D; Huthmacher C; Mathieson T; Poeckel D; Reader V; Strunk K; Sweetman G; Kruse U; Neubauer G; Ramsden NG; Drewes G
Nat Biotechnol; 2011 Mar; 29(3):255-65. PubMed ID: 21258344
[TBL] [Abstract][Full Text] [Related]
23. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes.
Lombardi PM; Cole KE; Dowling DP; Christianson DW
Curr Opin Struct Biol; 2011 Dec; 21(6):735-43. PubMed ID: 21872466
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylases: structural determinants of inhibitor selectivity.
Micelli C; Rastelli G
Drug Discov Today; 2015 Jun; 20(6):718-35. PubMed ID: 25687212
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylases as therapeutic targets--from cancer to cardiac disease.
Abend A; Kehat I
Pharmacol Ther; 2015 Mar; 147():55-62. PubMed ID: 25444758
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.
Falkenberg KJ; Johnstone RW
Nat Rev Drug Discov; 2014 Sep; 13(9):673-91. PubMed ID: 25131830
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors and cell death.
Zhang J; Zhong Q
Cell Mol Life Sci; 2014 Oct; 71(20):3885-901. PubMed ID: 24898083
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents.
Ververis K; Hiong A; Karagiannis TC; Licciardi PV
Biologics; 2013; 7():47-60. PubMed ID: 23459471
[TBL] [Abstract][Full Text] [Related]
29. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men.
Yang XJ; Seto E
Nat Rev Mol Cell Biol; 2008 Mar; 9(3):206-18. PubMed ID: 18292778
[TBL] [Abstract][Full Text] [Related]
30. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.
Haggarty SJ; Koeller KM; Wong JC; Grozinger CM; Schreiber SL
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4389-94. PubMed ID: 12677000
[TBL] [Abstract][Full Text] [Related]
31. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.
Yoshida M; Kijima M; Akita M; Beppu T
J Biol Chem; 1990 Oct; 265(28):17174-9. PubMed ID: 2211619
[TBL] [Abstract][Full Text] [Related]
32. SIRT2 plays complex roles in neuroinflammation neuroimmunology-associated disorders.
Lu W; Ji H; Wu D
Front Immunol; 2023; 14():1174180. PubMed ID: 37215138
[TBL] [Abstract][Full Text] [Related]
33. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity.
Kim HS; Vassilopoulos A; Wang RH; Lahusen T; Xiao Z; Xu X; Li C; Veenstra TD; Li B; Yu H; Ji J; Wang XW; Park SH; Cha YI; Gius D; Deng CX
Cancer Cell; 2011 Oct; 20(4):487-99. PubMed ID: 22014574
[TBL] [Abstract][Full Text] [Related]
34. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.
Outeiro TF; Kontopoulos E; Altmann SM; Kufareva I; Strathearn KE; Amore AM; Volk CB; Maxwell MM; Rochet JC; McLean PJ; Young AB; Abagyan R; Feany MB; Hyman BT; Kazantsev AG
Science; 2007 Jul; 317(5837):516-9. PubMed ID: 17588900
[TBL] [Abstract][Full Text] [Related]
35. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase.
North BJ; Marshall BL; Borra MT; Denu JM; Verdin E
Mol Cell; 2003 Feb; 11(2):437-44. PubMed ID: 12620231
[TBL] [Abstract][Full Text] [Related]
36. Deacetylation of Septin4 by SIRT2 (Silent Mating Type Information Regulation 2 Homolog-2) Mitigates Damaging of Hypertensive Nephropathy.
Zhang Y; Zhang N; Zou Y; Song C; Cao K; Wu B; You S; Lu S; Wang D; Xu J; Huang X; Zhang P; Fan Z; Liu J; Cheng Z; Zhang Z; Kong C; Cao L; Sun Y
Circ Res; 2023 Mar; 132(5):601-624. PubMed ID: 36786216
[TBL] [Abstract][Full Text] [Related]
37. Promotion of Lung Cancer Metastasis by SIRT2-Mediated Extracellular Protein Deacetylation.
Wu M; Zhang JB; Xiong YW; Zhao YX; Zheng MG; Huang XL; Huang F; Wu XX; Li X; Fan WJ; Hu L; Zeng YY; Cheng XJ; Yue JC; Du JJ; Chen NN; Wei WX; Yao QH; Lu XM; Huang C; Deng J; Chang ZJ; Liu HB; Zhao TC; Chinn YE
Adv Sci (Weinh); 2023 Jan; 10(3):e2205462. PubMed ID: 36453571
[TBL] [Abstract][Full Text] [Related]
38. LINC01588 regulates WWP2-mediated cardiomyocyte injury by interacting with HNRNPL.
Song Y; Ren X; Gao F; Li F; Zhou J; Chen J; Zhang Y
Environ Toxicol; 2022 Jul; 37(7):1629-1641. PubMed ID: 35258167
[TBL] [Abstract][Full Text] [Related]
39. Deacetylation-dependent regulation of PARP1 by SIRT2 dictates ubiquitination of PARP1 in oxidative stress-induced vascular injury.
Zhang N; Zhang Y; Wu B; Wu S; You S; Lu S; Liu J; Huang X; Xu J; Cao L; Sun Y
Redox Biol; 2021 Nov; 47():102141. PubMed ID: 34555594
[TBL] [Abstract][Full Text] [Related]
40. Trajectories of kidney function in diabetes: a clinicopathological update.
Oshima M; Shimizu M; Yamanouchi M; Toyama T; Hara A; Furuichi K; Wada T
Nat Rev Nephrol; 2021 Nov; 17(11):740-750. PubMed ID: 34363037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
